The naive question first: if mRNA is just a molecule that tells your cells what to build, why can't you simply inject the mRNA? Because on its own, mRNA is one of the most fragile molecules in biology. Your body is full of enzymes whose entire job is to chew up loose RNA. Injected bare, it would be gone before it did anything.
Think of it like mailing a letter written in disappearing ink through a shredder factory. The message — the mRNA — is fine. The problem is delivery. The solution that made mRNA vaccines possible is the lipid nanoparticle, or LNP: a tiny sphere of fatty molecules that wraps the mRNA, shields it from the enzymes, and helps it slip inside your cells.
That is why so much of the 2021 patent record is about the bubble, not the message. CureVac's publication US20210251898A1 is titled, plainly, lipid nanoparticle mRNA vaccines — the claims cover the formulation that holds it all together.
Manufacturing the bubble consistently turns out to be its own hard problem. Publication US20210275689A1 covers processes of preparing mRNA-loaded lipid nanoparticles, and US20210046192A1 covers stable compositions of those particles and how to make them. In plain terms: it is not enough to invent the recipe; you have to be able to cook it the same way ten million times.
There is a reason this matters commercially. The mRNA sequence is relatively easy to change — swap the message and you target a new virus. The delivery system is the harder, more defensible asset. That is where the durable patents cluster, and it is why the LNP filings outnumber the sequence filings.
So when you hear 'mRNA technology,' the short version is that the headline molecule is only half the invention. The other half is the fatty envelope that gets it where it needs to go — and in 2021, that envelope was where the patent action was.